4,314
Views
55
CrossRef citations to date
0
Altmetric
Review

Cell culture-based influenza vaccines: A necessary and indispensable investment for the future

Pages 1223-1234 | Received 21 Oct 2014, Accepted 16 Jan 2015, Published online: 27 May 2015

References

  • Rappuoli R, Pizza M, del Guidice G, de Gregorio E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci U SA 2014; 111:12288-93; PMID:25136130; http://dx.doi.org/10.1073/pnas.1402981111
  • Morens DM, Taubenberger JK, Folkers GK, Fauci AS. Pandemic influenza's 500th anniversary. Clin Infect Dis 2010; 51:1442-4; PMID:21067353; http://dx.doi.org/10.1086/657429
  • Nair H, Simões EA, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JS, Feikin DR, Mackenzie GA, Moïsi JC, Roca A, Baggett HC, et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet 2013; 381:1380-90; PMID:23369797; http://dx.doi.org/10.1016/S0140-6736(12)61901-1
  • Carrillo-Santisteve P, Ciancio BC, Nicoll A, Lopalco PL. The importance of influenza prevention for public health. Hum Vaccin Immunother 2012; 8:89-95; PMID:22251992; http://dx.doi.org/10.4161/hv.8.1.19066
  • Jit M, Newall AT, Beutels P. Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. Hum Vaccin Immunother 2013; 9:834-40; PMID:23357859; http://dx.doi.org/10.4161/hv.23637
  • de Waure C. Veneziano MA, Cadeddu C, Capizzi S, Specchia ML, Capri S, Ricciardi W. Economic value of influenza vaccination. Hum Vaccin Immunother 2012; 8:119-29; PMID:22251999; http://dx.doi.org/10.4161/hv.8.1.18420
  • Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, Shupo F, Samson SI. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health 2014; 14:813; PMID:25103091; http://dx.doi.org/10.1186/1471-2458-14-813
  • Chiu C, Ellebedy AH, Wrammert J, Ahmed R. B cell responses to influenza infection and vaccination. Curr Top Microbiol Immunol 2014; 386:381-98; Epub ahead of print, Sep 6; PMID:25193634; http://dx.doi.org/10.1007/82_2014_425
  • Fox A, Mai LQ, Thanh LT, Wolbers M, Le Khanh Hang N, Thai PQ, Thu Yen NT, Minh Hoa LN, Bryant JE, Duong TN, et al. Hemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infection. J Infect 2015; 70:187-96. http://dx.doi.org/10.1016/j.jinf.2014.09.003
  • Babon JA, Cruz J, Orphin L, Pazoles P, Co MD, Ennis FA, Terajima M. Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases. Hum Immunol 2009; 70:711-21; PMID:19524006; http://dx.doi.org/10.1016/j.humimm.2009.06.004
  • Rimmelzwaan GF, Kreijtz JH, Bodewes R, Fouchier RA, Osterhaus AD. Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 2009; 27:6363-5; PMID:19840674; http://dx.doi.org/10.1016/j.vaccine.2009.01.016
  • Grant E, Wu C, Chan KF, Eckle S, Bharadwaj M, Zou QM, Kedzierska K, Chen W. Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses. Immunol Cell Biol 2013; 91:184-94; PMID:23399741; http://dx.doi.org/10.1038/icb.2012.78
  • Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274-80; PMID:22286307; http://dx.doi.org/10.1038/nm.2612
  • Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013; 19:1305-12; PMID:24056771; http://dx.doi.org/10.1038/nm.3350
  • Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng N-Y, Nishtala M, Wrammert J, Smith K, James JA, et al. Limited efficacy of inactivated influenza vaccine in the elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest 2014; 121:3109-19; http://dx.doi.org/10.1172/JCI57834
  • McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, Hager WD, Barry MB, Kleppinger A, Wang Y, Bleackley RC. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009; 27:2418-25; PMID:19368783; http://dx.doi.org/10.1016/j.vaccine.2009.01.136
  • Hsu JP, Phoon MC, Koh GC, Chen MI, Lee VJ, Wu Y, Xie ML, Cheong A, Leo YS, Chow VT. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers. Int J Infect Dis 2012; 16:e621-7; PMID:22704721; http://dx.doi.org/10.1016/j.ijid.2012.04.010
  • Dolfi DV, Mansfield DK, Kurupati RK, Kanan S, Doyle SA, Ertl HC, Schmader KE, Wherry EJ. Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans. PLoS One 2013; 8:e77164; PMID:24155927; http://dx.doi.org/10.1371/journal.pone.0077164
  • Miller MS, Palese P. Peering into the crystal ball: influenza pandemics and vaccine efficacy. Cell 2014; 157:294-9; PMID:24725400; http://dx.doi.org/10.1016/j.cell.2014.03.023
  • Cox RJ. Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother 2013; 9:405-8; PMID:23291930; http://dx.doi.org/10.4161/hv.22908
  • Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Exp Rev Vaccines 2013; 12:519-36; PMID:23659300; http://dx.doi.org/10.1586/erv.13.35
  • Bonduelle O, Carrat F, Luyt CE, Leport C, Mosnier A, Benhabiles N, Krivine A, Rozenberg F, Yahia N, Samri A, et al. Characterization of pandemic influenza immune memory signature after vaccination or infection. J Clin Invest 2014; 124:3129-36; PMID:24911149; http://dx.doi.org/10.1172/JCI74565
  • He XS, Holmes TH, Mahmood K, Kemble GW, Dekker CL, Arvin AM, Greenberg HB. Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J Infect Dis 2008; 197:803-11; PMID:18279048; http://dx.doi.org/10.1086/528804
  • Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011; 204:845-53; PMID:21846636; http://dx.doi.org/10.1093/infdis/jir436
  • Rudenko L, Kiseleva I, Naykhin AN, Erofeeva M, Stukova M, Donina S, Petukhova G, Pisareva M, Krivitskaya V, Grudinin M, et al. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine. PLoS One 2014; 9:e87962; PMID:24533064; http://dx.doi.org/10.1371/journal.pone.0087962
  • Sasaki S, Holmes TH, Albrecht RA, Garcia-Sastre A, Dekker CL, He XS, Greenberg HB. Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines. J Infect Dis 2014; 210:865-74; PMID:24676204; http://dx.doi.org/10.1093/infdis/jiu190
  • Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158-66; PMID:22551811; http://dx.doi.org/10.1093/infdis/jis330
  • Nayak JL, Fitzgerald TF, Richards KA, Yang H, Treanor JJ, Sant AJ. CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine. J Infect Dis 2013; 207:297-305; PMID:23148285; http://dx.doi.org/10.1093/infdis/jis684
  • Pedersen GK, Madhun AS, Beakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158-66; PMID:22551811; http://dx.doi.org/10.1093/infdis/jis330
  • Edwards EM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169:68-76; PMID:8277200; http://dx.doi.org/10.1093/infdis/169.1.68
  • Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza vaccine. J Infect Dis 2000; 181(3):1133-1137; PMID:10720541; http://dx.doi.org/10.1086/315323
  • Beyer WE, Palache AM, de Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002; 20(9–10):134-153; PMID:11818152; http://dx.doi.org/10.1016/S0264-410X(01)00471-6
  • Lee MS, Mahmood K, Adhikary L, August JM, Cordova J, Cho I, Kemble G, Reisinger K, Walker RE, Mendelman PM. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr Infect Dis J 2004; 23:852-6; PMID:15361726; http://dx.doi.org/10.1097/01.inf.0000137566.87691.3b
  • Sasaki S, Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW, Arvin AM, Greenberg HB. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza vaccines. J Virol 2007; 81:215-28; PMID:17050593; http://dx.doi.org/10.1128/JVI.01957-06
  • Lu B, Zhou H, Ye D, Kemble G, Jin H. Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics. J Virol 2005; 79:6763-71; PMID:15890915; http://dx.doi.org/10.1128/JVI.79.11.6763-6771.2005
  • Horimoto T, Takada A, Fujii K, Goto H, Hatta M, Watanabe S, Iwatsuki-Horimoto K, Ito M, Tagawa-Sakai Y, Yamada S, et al. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 2006; 24:3669-76; PMID:16378663; http://dx.doi.org/10.1016/j.vaccine.2005.07.005
  • Donis RO; The Influenza Cell Culture Working Group. Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing. Vaccine 2014; 32(48):6583-90; Epub ahead of print, Jun 24; http://dx.doi.org/10.1016/j.vaccine.2014.06.045
  • Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC. Alternations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985; 143:166-74; PMID:4060580; http://dx.doi.org/10.1016/0042-6822(85)90105-9
  • Katz JM, Naeve CW, Webster RG. Host cell-mediated variation in H3N2 influenza viruses. Virology 1987; 156:386-95; PMID:3811239; http://dx.doi.org/10.1016/0042-6822(87)90418-1
  • Robertson JS, Bootman JS, Newman R, Oxford JS, Daniels RS, Webster RG, Schild GC. Structural changes in the hemagglutinin which accompany egg adaptation of an influenza A (H1N1) virus. Virology 1987; 160:31-7; PMID:3629978; http://dx.doi.org/10.1016/0042-6822(87)90040-7
  • Katz JM, Webster RG. Antigenic and structural characterization of multiple subpopulations of H3N2 influenza virus from an individual. Virology 1988; 165:446-56; PMID:3407150; http://dx.doi.org/10.1016/0042-6822(88)90588-0
  • Wang ML, Katz JM, Webster RG. Extensive heterogeneity in the hemagglutinin of egg-grown influenza viruses from different patients. Virology 1989; 171:275-9; PMID:2741346; http://dx.doi.org/10.1016/0042-6822(89)90538-2
  • Katz JM, Webster RG. Amino acid sequence identity between the HA1 of influenza A (H3N2) viruses grown in mammalian and primary chick kidney cells. J Gen Virol 1992; 73:1159-65; PMID:1588320; http://dx.doi.org/10.1099/0022-1317-73-5-1159
  • Wood JM, Oxford JS, Dunleavy U, Newman RW, Major D, Robertson JS. Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule. Virology 1989; 171:214-21; PMID:2741341; http://dx.doi.org/10.1016/0042-6822(89)90528-X
  • Kodihalli S, Justewicz DM, Gubareva LV, Webster RG. Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. J Virol 1995; 69:4888-97; PMID:7609057
  • Alymova IV, Kodihalli S, Govorkova EA, Fanget B, Gerdil C, Webster RG. Immunogenicity and protective efficacy in mice of influenza B virus vaccines growth in mammalian cells. J Virol 1998; 72:4472-7; PMID:9557744
  • Katz JM, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989; 160:191-8; PMID:2760480; http://dx.doi.org/10.1093/infdis/160.2.191
  • Govorkova EA, Kodihalli S, Alymova IV, Fanget B, Webster RG. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. Dev Biol Stand 1999; 98:39-51; PMID:10494958
  • Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005; 23:2943-52; PMID:15780743; http://dx.doi.org/10.1016/j.vaccine.2004.08.054
  • Jung EJ, Lee KH, Seong BL. Reverse genetic platform for inactivated and live-attenuated influenza vaccine. Exp Mol Med 2010; 42:116-21; PMID:20054235; http://dx.doi.org/10.3858/emm.2010.42.2.013
  • Katz JM, Wang M, Webster RG. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals identity with mammalian cell-grown virus. J Virol 1990; 64:1808-11; PMID:2319652
  • Robertson JS, Bootman JS, Nicolson C, Major D, Robertson EW, Wood JM. The hemagglutinin of influenza B virus present in clinical material is a single species identical to that of mammalian cell-grown virus. Virology 1990; 179:35-40; PMID:2219728; http://dx.doi.org/10.1016/0042-6822(90)90270-2
  • Robertson JS, Nicolson C, Bootman JS, Major D, Robertson EW, Wood JM. Sequence analysis of the haemagglutinin (HA) of influenza A (H1N1) viruses present in clinical material and comparison with the HA of laboratory-derived virus. J Gen Virol 1991; 72:2671-77; PMID:1940864; http://dx.doi.org/10.1099/0022-1317-72-11-2671
  • Govorkova EA, Murti G, Meigneier B, deTaisne C, Webster RG. African green monkey (Vero) cells provide an alternative host cell system for influenza A and B viruses. J Virol 1996; 70:5519-24; PMID:8764064
  • Kishida N, Fujisaki S, Yokoyama M, Sato H, Saito R, Ikematsu H, Xu H, Takashita E, Tashiro M, Takao S, et al. Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs. Clin Vac Immunol 2012; 19:897-908; PMID:22492743; http://dx.doi.org/10.1128/CVI.05726-11
  • Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 2009; 8:607-18; PMID:19397417; http://dx.doi.org/10.1586/erv.09.19
  • Desmyter J, Melnick JL, Rawls WE. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol 1968; 2:955-61; PMID:4302013
  • Govorkova EA, Kaverin NV, Gubareva LV, Meignier B, Webster RG. Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero). J Infect Dis 1995; 172:250-3; PMID:7797924; http://dx.doi.org/10.1093/infdis/172.1.250
  • Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bandixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998; 16:960-8; PMID:9682344; http://dx.doi.org/10.1016/S0264-410X(97)00301-0
  • Zhou F, Zhou J, Ma L, Song S, Zhang X, Li W, Jiang S, Wang Y, Liao G. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1. Biochem Biophys Res Commun 2012; 421:850-4; PMID:22554519; http://dx.doi.org/10.1016/j.bbrc.2012.04.101
  • Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Eder G, Dorner F. Development of a Vero cell-derived influenza whole virus vaccine. Dev Biol Stand 1999; 98:101-10; discussion 111; PMID:10494963
  • Kistner O, Howard MK, Spruth M, Wodal W, Brühl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M, et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007; 25:6028-36; PMID:17614165; http://dx.doi.org/10.1016/j.vaccine.2007.05.013
  • Whiteley A, Major D, Legastelois I, Campitelli L, Donatelli I, Thompson CI, Zambon MC, Wood JM, Barclay WS. Generation of candidate human influenza vaccine strains in cell culture – rehearsing the European response to an H7N1 pandemic threat. Infl Other Resp Viruses 2007; 1:157-66; PMID:19432631; http://dx.doi.org/10.1111/j.1750-2659.2007.00022.x
  • Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem 2008; 389:569-77; PMID:18953724; http://dx.doi.org/10.1515/BC.2008.060
  • Kistner O, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, Sabarth N, Falkner FG, Mayerhofer I, Mundt W, Reiter M, et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 2010; 5:e9349; PMID:20186321; http://dx.doi.org/10.1371/journal.pone.0009349
  • Bruhl P, Kerschbaum A, Kistner O, Barrett N, Dorner F, Gerencer M. Humoral and cell-mediated immunity to Vero cell-derived influenza vaccine. Vaccine 2000; 19:1149-58; PMID:11137251; http://dx.doi.org/10.1016/S0264-410X(00)00316-9
  • Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:2573-84; PMID:18550874; http://dx.doi.org/10.1056/NEJMoa073121
  • Ehrlich HJ, Muller M, Fritsch S, Zeitlinger M, Berezuk G, Loew-Baselli A, van der Velden MV, Pollabauer EM, Maritsch F, Pavlova BG, et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009; 200:1113-8; PMID:19712040; http://dx.doi.org/10.1086/605608
  • Keitel WA, Keitel WA, Dekker CL, Mink C, Campbell JD, Edwards KM, Patel SM, Ho DY, Talbot HK, Guo K, et al. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine 2009; 27:6642-8; PMID:19773098; http://dx.doi.org/10.1016/j.vaccine.2009.03.015
  • Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, et al. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 2012; 30:329-35; PMID:22080174; http://dx.doi.org/10.1016/j.vaccine.2011.10.088
  • van der Velden MV, Aichinger G, Pollabauer EM, Loew-Baselli A, Fritsch S, Benamara K, Kistner O, Muller M, Zeitlinger M, Kollaritsch H, et al. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine 2012; 30:6127-35; PMID:22884662; http://dx.doi.org/10.1016/j.vaccine.2012.07.077
  • van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, et al. Safety and immunogenicity of a Vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population. J Infect Dis 2014; 209:12-23; PMID:24041789; http://dx.doi.org/10.1093/infdis/jit498
  • Fritz R, Sabarth N, Kiermayr S, Hohenadl C, Howard MK, Ilk R, Kistner O, Ehrlich HJ, Barrett PN, Kreil TR. A Vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J Infect Dis 2012; 205:28-34; PMID:22090447; http://dx.doi.org/10.1093/infdis/jir711
  • Crowe BA, Bruhl P, Gerencer M, Schwendinger MG, Pilz A, Kistner O, Koelling-Schlebusch K, Aichinger G, Singer J, Zeitlinger M, et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 2010; 29:166-73; PMID:21055500; http://dx.doi.org/10.1016/j.vaccine.2010.10.065
  • Howard MK, Sabarth N, Savidis-Dacho H, Portsmouth D, Kistner O, Kreil TR, Ehrlich HJ, Barrett PN. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One 2011; 6:e23791; PMID:21876771; http://dx.doi.org/10.1371/journal.pone.0023791
  • Ehrlich HJ, Berezuk G, Fritsch S, Aichinger G, Singer J, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN. Clinical development of a Vero cell culture-derived seasonal influenza vaccine. Vaccine 2012; 30:4377-86; PMID:22172502; http://dx.doi.org/10.1016/j.vaccine.2011.11.114
  • Ehrlich HJ, Muller M, Kollaritsh H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, et al. Pre-vaccination immunity an immune responses to a cell culture-derived whole-virus H1N1 vaccine and similar to a seasonal influenza vaccine. Vaccine 2012; 30:4543-51; PMID:22475864; http://dx.doi.org/10.1016/j.vaccine.2012.03.061
  • Ehrlich HJ, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Portsmouth D, Kistner O, Barrett PN. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis 2012; 54:946-54; PMID:22267715; http://dx.doi.org/10.1093/cid/cir959
  • Loew-Baselli A, Pavlova BG, Fritsch S, Poellabauer EM, Draxler W, Kistner O, Behre U, Angemayr R, Neugebauer J, Kirsten K, et al. A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory. Vaccine 2012; 30:5956-66; PMID:22846396; http://dx.doi.org/10.1016/j.vaccine.2012.07.039
  • Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649; PMID:20508026; http://dx.doi.org/10.1136/bmj.c2649
  • Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O, Ehrlich HJ. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011; 377:751-9; PMID:21329971; http://dx.doi.org/10.1016/S0140-6736(10)62228-3
  • Frank AL, Couch RB, Griffis CA, Baxter BD. Comparison of different tissue cultures for isolation and quantitation of influenza and parainfluenza viruses. J Clin Microbiol 1979; 10:32-6; PMID:227920
  • Schepetuik SK, Kok T. The use of MDCK, MEK, and LLCMK2 cell lines with enzyme immunoassay for the isolation of influenza and parainfluenza viruses from clinical specimens. J Virol Methods 1993; 42:241-50; PMID:8390473; http://dx.doi.org/10.1016/0166-0934(93)90036-Q
  • Reina J, Fernandez-Baca V, Blanco I, Munar M. Comparison of Madin-Darby canine kidney cells (MDCK) with a green monkey continuous cell line (Vero) and human lung embryonated cells (MRC-5) in the isolation of influenza A virus from nasopharyngeal aspirates by shell vial culture. J Clin Microbiol 1997; 35:1900-1; PMID:9196221
  • Romanova J, Katinger D, Ferko B, Voglauer R, Mochalova L, Bovin N, Lim W, Katinger H, Egorov A. Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology 2003; 307:90-7; PMID:12667817; http://dx.doi.org/10.1016/S0042-6822(02)00064-8
  • Seitz C, Frensing T, Höper D, Kochs G, Reichl U. High yields of influenza A virus in Madin-Darby canine kidney cells are promoted by an insufficient interferon-induced antiviral state. J Gen Virol 2010; 91:1754-63; PMID:20357039; http://dx.doi.org/10.1099/vir.0.020370-0
  • Frensing T, Seitz C, Heynisch B, Patzina C, Kochs G, Reichl U. Efficient influenza B virus propagation due to deficient interferon-induced antiviral activity in MDCK cells. Vaccine 2011; 29:7125-9; PMID:21651940; http://dx.doi.org/10.1016/j.vaccine.2011.05.069
  • Seitz C, Isken B, Heynisch B, Rettkowski M, Frensing T, Reichl U. Trypsin promotes efficient influenza vaccine production in MDCK cells by interfering with the antiviral host response. Appl Microbiol Biotechnol 2012; 93:601-11; PMID:21915610; http://dx.doi.org/10.1007/s00253-011-3569-8
  • Liu J, Shi X, Schwartz R, Kemble G. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine 2009; 27:6460-3; PMID:19559113; http://dx.doi.org/10.1016/j.vaccine.2009.06.024
  • Hussain AI, Cordeiro M, Sevilla E, Liu J. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 2010; 28:3848-55; PMID:20307595; http://dx.doi.org/10.1016/j.vaccine.2010.03.005
  • van Wielink R, Kant-Eenbergen HC, Harmsen MM, Martens DE, Wijffels RH, Coco-Martin JM. Adaptation of a Madin-Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines. J Virol Methods 2011; 171:53-60; PMID:20933017; http://dx.doi.org/10.1016/j.jviromet.2010.09.029
  • Zhai W, Zhang DN, Mai C, Choy J, Jian G, Sra K, Galinski MS. Comparison of different cell substrates on the measurement of human influenza virus neutralizing antibodies. PLoS One 2012; 7:e52327; PMID:23284988; http://dx.doi.org/10.1371/journal.pone.0052327
  • Merten OW, Hannoun C, Manuguerra JC, Ventre F, Petres S. Production of influenza virus in cell cultures for vaccine preparation. Adv Exp Med Biol 1996; 397:141-51; PMID:8718593; http://dx.doi.org/10.1007/978-1-4899-1382-1_19
  • Genzel Y, Dietzsch C, Rapp E, Schwarzer J, Reichl U. MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation. Appl Microbiol Biotechnol 2010; 88:461-75; PMID:20617311; http://dx.doi.org/10.1007/s00253-010-2742-9
  • Youil R, Su Q, Toner TJ, Szymkowiak C, Kwan WS, Rubin B, Petrukhin L, Kiseleva I. Shaw AR, DiStefano D. Comparative study of influenza virus replication in Vero and MDCK cell lines. J Virol Methods 2004; 120:23-31; PMID:15234806; http://dx.doi.org/10.1016/j.jviromet.2004.03.011
  • Makizumi K, Kimachi K, Fukada K, Nishimura T, Kudo Y, Goto S, Odagiri T, Tahiro M, Kino Y. Timely production of A/Fujian-like influenza vaccine matching the 2003-2004 epidemic strain may have been possible using Madin-Darby canine kidney cells. Vaccine 2008; 26:6852-58; PMID:19149013; http://dx.doi.org/10.1016/j.vaccine.2008.09.075
  • Nishiyama K, Sgawara K, Nouchi T, Kawano N, Soejima K, Abe S, Mizokami H. Purification and cDNA cloning of a novel protease inhibitor secreted into culture supernatant by MDCK cells. Biologics 2008; 36:122-33; PMID:17892946; http://dx.doi.org/10.1016/j.biologicals.2007.07.004
  • Polymenidou M, Trusheim H, Stallmach L, Moos R, Julius C, Miele G, Lenz-Bauer C, Aguzzi A. Canine MDCK cell lines are refractory to infection with human and mouse prions. Vaccine 26:2601-14; PMID:18423803; http://dx.doi.org/10.1016/j.vaccine.2008.03.035
  • Wanich N, Bencharitiwong R, Tsai T, Nowak-Wegrzyn A. In vitro assessment of the allergenicity of a novel influenza vaccine produced in dog kidney cells in individuals with dog allergy. Ann Allergy Asthma Immunol 2010; 104:426-33; PMID:20486334; http://dx.doi.org/10.1016/j.anai.2010.03.012
  • Bencharitiwong R, Leonard S, Tsai T, Nowak-Węgrzyn A. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells. Hum Vaccin Immunother 2012; 8:863-5; PMID:22777093; http://dx.doi.org/10.4161/hv.20324
  • Merten OW, Manuguerra JC, Hannoun C, van der Werf S. Production of influenza virus in serum-free mammalian cell cultures. Dev Biol Stand 1999; 98:23-37; PMID:10494957
  • Voeten JT, Claas EC, Brands R, Palache AM, van Scharrenburg GJ, Rimmelzwaan GF, Osterhaus AD. Generation and characterization of reassortant influenza A viruses propagated in serum-free cultured MDCK-SF1 cells. Dev Biol Stand 1999; 98:77-87; PMID:10494961
  • Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 2001; 19:3444-50; PMID:11348709; http://dx.doi.org/10.1016/S0264-410X(01)00053-6
  • Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines 2009; 8:1681-92; PMID:19943763; http://dx.doi.org/10.1586/erv.09.128
  • Genzel Y, Vogel T, Buck J, Behrendt I, Ramirez DV, Schiedner G, Jordan I, Reichl U. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells. Vaccine 2014; 32:2770-81; PMID:24583003; http://dx.doi.org/10.1016/j.vaccine.2014.02.016
  • George M, Farooq M, Dang T, Cortes B, Liu J, Maranga L. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process. Biotechnol Bioeng 2010; 106:906-17; PMID:20589670; http://dx.doi.org/10.1002/bit.22753
  • Sun B, Yu X, Kong W, Sun S, Yang P, Zhu C, Zhang H, Wu Y, Chen Y, Shi Y, et al. Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor. Appl Microbiol Biotechnol 2013; 97:1063-70; PMID:22945265; http://dx.doi.org/10.1007/s00253-012-4375-7
  • Tapia F, Vogel T, Genzel Y, Behrendt I, Hirschel M, Gangemi JD, Reichl U. Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor. Vaccine 2014; 32:1003-11; PMID:24269322; http://dx.doi.org/10.1016/j.vaccine.2013.11.044
  • Lohr V, Genzel Y, Behrendt I, Scharfenberg K, Reichl U. A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor. Vaccine 2010; 28:6256-64; PMID:20638458; http://dx.doi.org/10.1016/j.vaccine.2010.07.004
  • Vlecken DH, Plegrim RP, Ruminski S, Bakker WA, van der Pol LA. Comparison of initial feasibility of host cell lines for viral vaccine production. J Virol Methods 2013; 193:28-41; PMID:23684847; http://dx.doi.org/10.1016/j.jviromet.2013.04.020
  • Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 1997; 176:S20-S23; PMID:9240689; http://dx.doi.org/10.1086/514169
  • Halperin SA, Nestruck AC, Eastwood BJ. Safety and immunogenicity of a new influenza vaccine growth in mammalian cell culture. Vaccine 1998; 16:1331-5; PMID:9682398; http://dx.doi.org/10.1016/S0264-410X(98)00011-5
  • Percheson PB, Trepanier P, Dugre R, Mabrouk T. A Phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line. Dev Biol Stand 1999; 98:127-132; PMID:10494965
  • Halperin SA, Smith B, Mabrouk T, Germain M, Trepanier P, Hassell T, Treanor J, Gauthier R, Mills EL. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002; 20:1240-7; PMID:11803087; http://dx.doi.org/10.1016/S0264-410X(01)00428-5
  • Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine 2009; 27:6022-9; PMID:19666152; http://dx.doi.org/10.1016/j.vaccine.2009.07.083
  • Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 2009; 27:786-91; PMID:19027046; http://dx.doi.org/10.1016/j.vaccine.2008.11.003
  • Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009; 200:849-57; PMID:19673652; http://dx.doi.org/10.1086/605506
  • Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009; 200:841-8; PMID:19673651; http://dx.doi.org/10.1086/605505
  • Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997-1004; PMID:20868284; http://dx.doi.org/10.1086/656578
  • Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr Infect Dis J 2012; 31:494-500; PMID:22301476; http://dx.doi.org/10.1097/INF.0b013e31824bb179
  • Oxford JS, Al-Jabri AA, Lambkin R, Palache AM, Fleming DM. Non-responders to egg grown influenza vaccine seroconvert after booster immunization with MDCK cell grown vaccine. Vaccine 2003; 21:2743-6; PMID:12798612; http://dx.doi.org/10.1016/S0264-410X(03)00214-7
  • Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuvanagi H, Kusadokoro H, Sawata H, et al. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Vaccine 2012; 30:5030-7; PMID:22472791; http://dx.doi.org/10.1016/j.vaccine.2012.03.053
  • Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. Vaccine 2012; 30:4820-7; PMID:22626675; http://dx.doi.org/10.1016/j.vaccine.2012.05.013
  • Reynales H, Astudillo P, de Valliere S, Hatz C, Schlagenhauf P, Rath B, Velentgas P, Farina A, Sales-Carmona V, Groth N. A prospective observational safety study on MF59® adjuvanted cell culture-derived vaccine, Celtura® during the A/H1N1 (2009) influenza pandemic. Vaccine 2012; 30:6436-43; PMID:22902681; http://dx.doi.org/10.1016/j.vaccine.2012.08.005
  • Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Thee⇓ W, Burchard GD, Cramer JP. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study. Hum Vaccin Immunother 2014; 10:441-8; PMID:24240428; http://dx.doi.org/10.4161/hv.27140
  • Pan SC, Kung HC, Kao TM, Wu H, Dong SX, Hu MH, Chou AH, Chong P, Hsieh SM, Chang SC. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan. J Microbiol Immunol Infect 2013; 46:448-55; PMID:23022464; http://dx.doi.org/10.1016/j.jmii.2012.08.002
  • Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. 2009. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine – preliminary report. New Engl J Med 2009; 361:2424-35; PMID:19745215; http://dx.doi.org/10.1056/NEJMoa0907650
  • Loebermann M, Voss U, Meyer S, Bosse D, Fritzche C, Klammt S, Frimmel S, Riebold D, Reisinger EC. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination. PLoS One 2013; 8:e70866; PMID:23976960; http://dx.doi.org/10.1371/journal.pone.0070866
  • Basavaraj VH, Sampath G, Hegde NR, Mohan VK, Ella KM. Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies. Vaccine 2014; 32:4592-7; PMID:24856782; http://dx.doi.org/10.1016/j.vaccine.2014.05.039
  • Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Sawata H, Nakura N, Jaeger RK, Lattanzi M. Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children. Adv Ther 2010; 27:444-57; PMID:20586002; http://dx.doi.org/10.1007/s12325-010-0043-4
  • Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G. A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Vaccine 2012; 30:3470-7; PMID:22446638; http://dx.doi.org/10.1016/j.vaccine.2012.03.017
  • Reisinger KS, Holmes SJ, Pedotti P, Arora AK, Lattanzi M. A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination. Hum Vaccin Immunother 2014; 10:(8):2395-407; [Epub ahead of print]; PMID:25424947; http://dx.doi.org/10.4161/hv.29393
  • Heldens J, Hulskotte E, Voeten T, Breedveld B, Verwey P, van Duijnhoven W, Rudenko L, van Damme P, van den Bosch H. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers. Vaccine 2014; 32:5118-24; PMID:24858566; http://dx.doi.org/10.1016/j.vaccine.2014.05.030
  • Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9:1909-17; PMID:9741429; http://dx.doi.org/10.1089/hum.1998.9.13-1909
  • Lewis JA, Brown EL, Duncan PA. Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev Biol (Basel) 2006; 123:165-76; discussion 183-97; PMID:16566444
  • Koudstaal W, Hartgroves L, Havenga M, Legastelois I, Ophorst C, Sieuwerts M, Zuijdgeest D, Vogels R, Custers J, de Boer-Luijtze E, et al. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine 2009; 27:2588-93; PMID:19428865; http://dx.doi.org/10.1016/j.vaccine.2009.02.033
  • Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001; 19:2716-21; PMID:11257414; http://dx.doi.org/10.1016/S0264-410X(00)00508-9
  • Hartgroves LC, Koudstaal W, McLeod C, Moncorgé O, Thompson CI, Ellis J, Bull C, Havenga MJ, Goudsmit J, Barclay WS. Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. Vaccine 2010; 28:2973-9; PMID:20188682; http://dx.doi.org/10.1016/j.vaccine.2010.02.012
  • Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M, Vogel FR, Barclay W, et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009; 27:1889-97; PMID:19368768; http://dx.doi.org/10.1016/j.vaccine.2009.01.116
  • Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36:59-74; PMID:886304; http://dx.doi.org/10.1099/0022-1317-36-1-59
  • Le Ru A, Jacob D, Transfiguracion J, Ansorge S, Henry O, Kamen AA. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine 2010; 28: 3661-71; PMID:20347632; http://dx.doi.org/10.1016/j.vaccine.2010.03.029
  • Lohr V, Genzel Y, Jordan I, Katinger D, Mahr S, Sandig V, Reichl U. Live attenuated influenza viruses produced in suspension process with avail AGE1.CR.pIX cells. BMC Biotechnol 2012; 12:79; PMID:23110398; http://dx.doi.org/10.1186/1472-6750-12-79
  • Jordan I, Vos A, Beilfuss S, Neubert A, Breul S, Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine 2009; 27:748-56; PMID:19071186; http://dx.doi.org/10.1016/j.vaccine.2008.11.066
  • Lohr V, Hadicke O, Genzel Y, Jordan I, Buntemeyer H, Klamt S, Reichl U. The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis. BMC Biotechnol 2014; 14:72; PMID:25077436; http://dx.doi.org/10.1186/1472-6750-14-72
  • Brown SW, Mehtali M. The avian EB66R cell line, application to vaccines, and therapeutic protein production. PDA J Pharm Sci Technol 2010; 64:419-25; PMID:21502045
  • Smith KA, Colvin CJ, Weber PS, Spatz SJ, Coussens PM. High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases. Vaccine 2008; 26:3778-82; PMID:18524432; http://dx.doi.org/10.1016/j.vaccine.2008.04.048
  • Coussens PM, Smith KA, Weber PS, Colvin CJ. Immortalized chick embryo cell line adapted to serum-free growth conditions and capable of replicating human and reassortant H5N1 influenza strains for vaccine production. Vaccine 2011; 29:8661-8; PMID:21911025; http://dx.doi.org/10.1016/j.vaccine.2011.08.122
  • Schultz-Cherry S, Dybdahl-Sissoko N, McGregor M, Hinshaw VS. Mink lung epithelial cells: unique cell line that supports influenza A and B virus replication. J Clin Microbiol 1998; 36:3718-20; PMID:9817906
  • Huang YT, Turchek BM. Mink lung cells and mixed mink lung and A549 cells for rapid detection of influenza virus and other respiratory viruses. J Clin Microbiol 2000; 38:422-3; PMID:10618131
  • Hamilton SB, Wyatt DE, Wahlgren BT, O'Dowd MK, Morrissey JM, Daniels DE, Lednicky JA. Higher titers of some H5N1 and recent human H1N1 and H3N2 influenza viruses in Mv1 Lu vs. MDCK cells. Virol J 2011; 8:66; PMID:21314955; http://dx.doi.org/10.1186/1743-422X-8-66
  • Nakamura K, Homma M. Protein synthesis in Vero cells abortively infected with influenza B virus. J Gen Virol 1981; 56:199-202; PMID:7299373; http://dx.doi.org/10.1099/0022-1317-56-1-199
  • Lau SC, Scholtissek C. Abortive infection of Vero cells by an influenza A virus (FPV). Virology 1995; 212:225-31; PMID:7676635; http://dx.doi.org/10.1006/viro.1995.1473
  • Kaverin NV, Webster RG. Impairment of multicycle influenza virus growth in Vero (WHO) cells by loss of trypsin activity. J Virol 1995; 69:2700-3; PMID:7884927
  • Roedig JV, Rapp E, Hoper D, Genzel Y, Reichl U. Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin. PLoS One 2011; 6:e27989; PMID:22163276; http://dx.doi.org/10.1371/journal.pone.0027989
  • Tseng YF, Hu AY, Huang ML, Yeh WZ, Weng TC, Chen YS, Chong P, Lee MS. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness. PLoS One 2011; 6:e24057; PMID:22022351; http://dx.doi.org/10.1371/journal.pone.0024057
  • Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, García-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 1999; 73:9679-82; PMID:10516084
  • Ozaki H, Govorkova EA, Li C, Xiong X, Webster RG, Webby RJ. Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. J Virol 2004; 78:1851-7; PMID:14747549; http://dx.doi.org/10.1128/JVI.78.4.1851-1857.2004
  • Krause PR. Use of MDCK Cells for Manufacture of Inactivated Influenza Vaccines: Introduction. Vaccines and Related Biological Products Advisory Committee, Center for Biologics Evaluation and Research, Taylor & Francis. 2005; www.fda.gov/ohrms/dockets/ac/05/slides/5-4188S1-1draft.PPT
  • Groner A, Vorlop J (inventors); Novartis Vaccines and Diagnostics, Inc., (assignee). Animal cells and processes for the replication of influenza viruses. 1997. Patent No. WO/1997/037000.
  • Liu J, Mani S, Schwartz R, Richman L, Tabor DE. Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine 2010; 28:1285-93; PMID:19944150; http://dx.doi.org/10.1016/j.vaccine.2009.11.023
  • Omeir RL, Teferedegne B, Foseh GS, Beren JJ, Snoy PJ, Brinster LR, Cook JL, Peden K, Lewis AM Jr. Heterogeneity of the tumorigenic phenotype expressed by Madin-Darby canine kidney cells. Comp Med 2011; 61:243-50; PMID:21819694
  • Vepachedu RS, Menon A, Hussain AI, Liu J. Evaluation of tumorigenic potential of high yielding cloned MDCK cells for live-attenuated influenza vaccine using in vitro growth characteristics, metastatic gene expression and in vivo nude mice model. Biologicals 2012; 40:482-94; PMID:22902973; http://dx.doi.org/10.1016/j.biologicals.2012.06.005
  • Madin-Darby canine kidney continuous cell line. Briefing document, Solvay Pharmaceuticals, Vaccines and Related Biologicals Advisory Committee (VRBPAC), Center for Biologics Evaluation and Research, Taylor & Francis. 2005; http://www.fda.gov/ohrms/dockets/ac/05/briefing/5-4188b1_19a.pdf
  • Use of Madin Darby canine kidney cells for the manufacture of live, attenuated influenza vaccines. Briefing document, MedImmune, Vaccines and Related Biologicals Advisory Committee (VRBPAC), Center for Biologics Evaluation and Research, Taylor & Francis. 2008; http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4384B1_4.pdf
  • Onions D, Egan W, Jarrett R, Novicki D, Gregersen JP. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 2010; 38:544-51; PMID:20537553; http://dx.doi.org/10.1016/j.biologicals.2010.04.003
  • Hegde NR, Kumar D, Rao PP, Kumari PK, Kaushik Y, Ravikrishnan R, Prasad SD, Ella KM. Development and preclinical testing of HNVAC, a cell culture-based H1N1 pandemic influenza vaccine from India. Vaccine 2014; 32:3636-43; PMID:24801052; http://dx.doi.org/10.1016/j.vaccine.2014.04.072
  • Lewis AM Jr, Krause P, Peden K. A defined-risk approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture. Dev Biol 2001; 106:513-35; PMID:11761266
  • Medema JK, Meijer J, Kersten AJ, Horton R. Safety assessment of Madin Darby canine kidney cells as vaccine substrate. Dev Biol 2006; 123:243-50; PMID:16566450
  • Gregersen JP. A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines. Vaccine 2008; 26:3297-304; PMID:18468737; http://dx.doi.org/10.1016/j.vaccine.2008.03.076
  • Gregersen JP. A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine 2008; 26:3332-40;PMID:18485545; http://dx.doi.org/10.1016/j.vaccine.2008.03.075
  • Murata H, Macauley J, Lewis AM Jr, Peden K. Plaque purification as a method to mitigate the risk of adventitious-agent contamination in influenza vaccine virus seeds. Vaccine 2011; 29:3155-61; PMID:21354480; http://dx.doi.org/10.1016/j.vaccine.2011.02.041
  • Hess RD, Weber F, Watson K, Schmitt S. Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines. Vaccine 2012; 30:2715-27; PMID:22342707; http://dx.doi.org/10.1016/j.vaccine.2012.02.015
  • Roth B, Mohr H, Enders M, Garten W, Gregersen JP. Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses. Vaccine 2012; 30:517-22; PMID:22119922; http://dx.doi.org/10.1016/j.vaccine.2011.11.063
  • Ledwith BJ, Lanning CL, Gumprecht LA, Anderson CA, Coleman JB, Gatto NT, Balasubramanian G, Farris GM, Kemp RK, Harper LB, et al. Tumorigenicity assessments of Per.ER C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line. Dev Biol 2006; 123:251-63; discussion 265; PMID:16566451
  • Robertson JS, Cook P, Attwell AM, Williams SP. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue culture-derived virus: implications for vaccine manufacture. Vaccine 1995; 13:1583-8; PMID:8578846; http://dx.doi.org/10.1016/0264-410X(95)00085-F
  • Lin YP, Wharton SA, Martin J, Skehel JJ, Wiley DC, Steinhauer DA. Adaptation of egg-grown and transfectant influenza viruses for growth in mammalian cells: selection of hemagglutinin mutants with elevated pH of membrane fusion. Virology 1997; 233:402-10; PMID:9217063; http://dx.doi.org/10.1006/viro.1997.8626
  • Lee HK, Tang JW, Kong DH, Loh TP, Chiang DK, Lam TT, Koay ES. Comparison of mutation patterns in full-genome A/H3N2 influenza sequences obtained directly from clinical samples and the same samples after a single MDCK passage. PLoS One 2013; 8:e79252; PMID:24223916; http://dx.doi.org/10.1371/journal.pone.0079252
  • Opitz L, Zimmermann A, Lehmann S, Genzel Y, Lübben H, Reichl U, Wolff MW. Capture of cell culture-derived influenza virus by lectins: strain independent, but host cell dependent. J Virol Methods 2008; 154:61-8; PMID:18840469; http://dx.doi.org/10.1016/j.jviromet.2008.09.004
  • Hutter J, Rodig JV, Hoper D, Seeberger PH, Reichl U, Rapp E, Lepenies B. Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity. J Immunol 2013; 190:220-30; PMID:23225881; http://dx.doi.org/10.4049/jimmunol.1201060

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.